> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Epidermolysis Bullosa Drug Development
- URL: https://www.fdaweb.com/guide-on-epidermolysis-bullosa-drug-development-3/
- Published: 2019-07-08T12:00:00.000Z
- Updated: 2026-09-15T01:36:10.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144460

*Federal Register* notice: FDA has made available a final guidance entitled “Epidermolysis Bullosa (EB): Developing Drugs for Treatment of Cutaneous Manifestations.” The document focuses on drug development and trial design issues specific to the treatment of EB, including FDA’s current thinking on clinical trial endpoint considerations. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-07-01/pdf/2019-13969.pdf?ref=fdaweb.com).